Skip to content
Facebook Twitter Linkedin
InMed-logo-01
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Pharmaceutical
    • Cannabinoids in Development
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Neurodegenerative Disease
    • Novel Cannabinoid Analogs
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
    • Rare Cannabinoid Ingredients
  • Investors
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM Materials
    • Filings
    • Presentations
    • Media and Videos
  • Corporate
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos

Press Releases

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement of C$250,000

July 19, 2016
Read More »

InMed Announces Appointment of Eric A. Adams as CEO, President and Director

June 16, 2016
Read More »

InMed Announces Appointment of William J. Garner, M.D. to its Board of Directors

June 13, 2016
Read More »

InMed Updates Progress of its Epidermolysis Bullosa Program

May 18, 2016
Read More »

InMed Pharmaceuticals Provides Strategic Update on its Business Plans, Announces Planned Executive and Board Departures

May 4, 2016
Read More »

InMed Announces Update on Biosynthesis Project

February 16, 2016
Read More »

InMed Strengthens Board with Appointment of Experienced Biotech Executive Adam Cutler

November 23, 2015
Read More »

InMed Provides Update on Progress of its Development Program for Epidermolysis Bullosa

November 4, 2015
Read More »

InMed Pharmaceuticals, Inc. Announces Non-Brokered Private Placement for up to C$1,000,000

November 2, 2015
Read More »

InMed Appoints Paul Brennan as President & Chief Executive Officer

September 3, 2015
Read More »

InMed Commences Development of Proprietary Drug Delivery System

September 2, 2015
Read More »

InMed Appoints Paul Brennan to the Board of Directors

August 25, 2015
Read More »

InMed Pharmaceuticals Announces Progress in Orofacial Pain Program

August 20, 2015
Read More »

InMed Announces Positive In-Vitro Study Results of INM-750 Targeting Epidermolysis Bullosa Simplex (EBS)

August 6, 2015
Read More »

InMed Adds Chronic Obstructive Pulmonary Disease (COPD) Program to Therapeutic Pipeline

June 3, 2015
Read More »

InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)

May 26, 2015
Read More »

InMed Pharmaceuticals Files Provisional Patent for Compositions Treating Eye Diseases

May 12, 2015
Read More »

InMed Pharmaceuticals, Inc. Closes Non-Brokered Private Placement for C$1,232,750

May 7, 2015
Read More »

InMed Engages Peter Mountford as Strategic Advisor

May 5, 2015
Read More »

InMed Pharmaceuticals Qualifies for Electronic Trading in the U.S.

April 30, 2015
Read More »
« Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Next »

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Pharmaceutical

  • Cannabinoids in Development
  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Neurodegenerative Disease
  • Novel Cannabinoid Analogs

MANUFACTURING

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis
  • Rare Cannabinoid Ingredients

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

CORPORATE

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2023 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

"*" indicates required fields

Name*
Consent